曲美替尼
达布拉芬尼
医学
肺癌
V600E型
MEK抑制剂
癌症研究
突变
肿瘤科
突变体
靶向治疗
MAPK/ERK通路
癌症
内科学
激酶
黑色素瘤
威罗菲尼
基因
生物
转移性黑色素瘤
遗传学
作者
Mariona Riudavets,Priscilla Cascetta,David Planchard
出处
期刊:Lung Cancer
[Elsevier]
日期:2022-07-01
卷期号:169: 102-114
被引量:9
标识
DOI:10.1016/j.lungcan.2022.05.014
摘要
Lung cancer harbouring BRAF mutations accounts for 4% of all non-small cell lung cancer (NSCLC) cases, identifying a relevant subset of patients that need to be promptly managed. Three subtypes of BRAF mutations have been described: class I (V600E), and class II and III (non-V600), with different prognostic and predictive outcomes. Pivotal phase II trials have demonstrated the efficacy of the double BRAF/MEK inhibition with dabrafenib plus trametinib in patients harbouring V600E mutations, making BRAF a mandatory requirement in the genetic portrait of advanced non-squamous lung cancer patients. However, non-V600 mutations represent around 50% of BRAF-mutant NSCLC patients, for which no specific targeted approaches are approved. A paradigm shift from the double BRAF/MEK inhibition to combinations with agents with distinct mechanisms of action, such as immune-checkpoint inhibitors, pan-RAF and selective ERK 1/2 inhibitors, is under investigation and may change the therapeutic landscape of BRAF-driven NSCLC. This paper provides a practical, concise and updated review on the therapeutic strategies in NSCLC with BRAF mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI